Special Issue "Nutraceutical Supplements in Heart Failure"
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 10241
Interests: nutraceuticals; heart failure; endothelial dysfunction; metabolic syndrome
Special Issues, Collections and Topics in MDPI journals
Heart failure (HF) is a multifactorial disease with a prevalence of 1–2% in the global population. Co-morbidities such as diabetes, hypertension, obesity, or dyslipidemia are frequently associated with the occurrence of HF, thereby increasing the prevalence of the disease and the rate of hospitalization and mortality. In addition, ageing is affecting the number of patients undergoing HF, as the prevalence of the disease rises to 10% in people aged >70 years. Better management of risk factors and more substantial pharmacological and non-pharmacological treatment according to recent guidelines have significantly reduced the impact of HF and its consequences. In particular, recent data showed that all-cause mortality prevalence at 12 months for hospitalized and stable/ambulatory HF patients were 17% and 7%, respectively, and the 12-month hospitalization rates were 44% and 32%, respectively. Thus, several relevant outcomes of HF still remain unsatisfactory, and further improvements to the impact of the disease have to be taken into account while considering the overall approach to the management of the disease. Although preliminary evidence suggests that HF is associated with an increased deficiency of micronutrients and that nutraceuticals supply could be beneficial in treating patients undergoing failing myocardium, limited evidence supporting the benefits of nutraceuticals for patients with HF has been found in recent studies and meta-analyses.
The present Special Issue aims to collect contributions in this field in order to:
- Identify a pathophysiological basis for nutraceutical supplementation at the early stages of cardiomyocyte dysfunction;
- Optimize the nutraceutical supplementation process based on specific targets of myocardial dysfunction, in both animal models of HF and patients, with ejection fraction either preserved or compromised;
- Promote and design clinical trials in order to verify, by means of an approach from “trees to bedside” , the efficacy and safety of nutraceutical supplementation in HF.
Prof. Dr. Vincenzo Mollace
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Heart failure
- Cardiomyocyte dysfunction
- Nutraceutical supplementation